ClinicalTrials.gg
RecruitingNCT06128629Updated Nov 4, 2026

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

A Phase 3 interventional study of NTLA-2001 and Placebo in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Intellia Therapeutics. Recruiting at 138 sites in 26 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Intellia Therapeutics · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 4, 2026Site recruiting status changed7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States — 10 open to participants now, 12 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · United States.

Planned enrollment
Largest of 23
1,200 · median 150
Started
2023
with 4 others
Phase 3
10 of 37
3 open now
Primary completion
2027-12
later than 4 of 11 live
Registered
31st of 37
by date

Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, this one has the largest planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 31st registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

10 of the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Read the detailed description

This is a multinational, multicenter, double-blind, placebo-controlled study in approximately 1200 participants, who will be randomized to receive a single infusion of either NTLA-2001 or placebo.

03

Conditions studied

  • Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Keywords

  • TTR
  • Amyloidosis
  • Cardiomyopathy
  • NTLA-2001
  • ATTR-CM
  • Transthyretin
  • ATTR
  • TTR-mediated amyloidosis
  • Amyloidosis, Hereditary
  • Amyloidosis, Hereditary, Transthyretin-Related Amyloidosis
  • Transthyretin amyloid cardiomyopathy
  • TTR cardiomyopathy
  • Wild-type TTR
  • V122I
  • Amyloidosis, Wild Type
  • CRISPR/Cas9
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of ATTR amyloidosis with cardiomyopathy
  • Medical history of heart failure (HF)
  • Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention
  • Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 600 pg/mL and less than 10,000 pg/mL

Exclusion criteria

Exclusion Criteria:

  • (NYHA) Class IV HF
  • Polyneuropathy Disability score of IV (confined to wheelchair or bed)
  • Has , or (HIV) infection
  • History of active within 3 years prior to screening
  • RNA silencer therapy (patisiran, inotersen and/or eplontersen) within 12 months prior to dosing. Any prior vutrisiran use is not allowed
  • Initiation of tafamidis or acoramidis within 56 days prior to study dosing
  • Estimated (eGFR) \<30 mL/min/1.73m\^2
  • History of liver disease
  • Uncontrolled blood pressure
  • Unable or unwilling to take vitamin A supplementation for the duration of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    NTLA-2001

    Single intravenous (IV) infusion of NTLA-2001

    Biological: NTLA-2001

  • Placebo comparator
    Placebo

    Single IV infusion of normal saline

    Drug: Placebo

Interventions

  • BiologicalNTLA-2001

    NTLA-2001 (55mg) by IV infusion

  • DrugPlacebo

    Normal saline (0.9% NaCl) by IV infusion

06

What researchers measure

Primary outcomes

  1. Composite outcome of cardiovascular (CV) mortality and CV events

    Time frame: Maximum study duration is dependent on event rates and is estimated to be at least 18 months and up to approximately 5 years

Secondary outcomes

  1. Change in baseline to month 18 in serum TTR

    Time frame: Baseline, Month 18

  2. Change from baseline to month 18 in KCCQ-OS score

    Time frame: Baseline, Month 18

07

Study locations

128 of 138 sites recruiting

Showing the first 100 of 138 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Nov 13, 2023
StartActual
Dec 13, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 1 site removed. 7 sites changed recruiting status (4 now recruiting, 3 now withdrawn)
Show 7 sites
  • University of Arizona · Tucson, United StatesRecruiting→Withdrawn
  • Centro Hospitalar Universitario do Porto · Porto, PortugalRecruiting→Withdrawn
  • Synexus Midlands Clinical Research Centre · Birmingham, United KingdomActive, not recruiting→Recruiting
  • Synexus Wales Clinical Research Centre · Cardiff, United KingdomActive, not recruiting→Recruiting
  • Synexus Scotland Clinical Research Centre · Glasgow, United KingdomActive, not recruiting→Recruiting
  • Synexus Hexham Clinical Research Centre · Hexham, United KingdomActive, not recruiting→Withdrawn
  • Synexus Manchester Clinical Research Centre · Manchester, United KingdomActive, not recruiting→Recruiting
Show 7 added (2 Brazil, 1 United States, 1 Canada, 1 Germany, 1 Israel, 1 Netherlands)
  • University of Wisconsin - Madison · Madison, United States
  • UNICAMP · Campinas, Brazil
  • Instituto de Educacao, Pesquisa e Gestao em Saude · Rio de Janeiro, Brazil
  • Montreal Heart Institute · Montreal, Canada
  • LMU Klinikum Muenchen · Munich, Germany
  • Sheba Medical Center · Tel HaShomer, Israel
  • Maastricht University Medical Center · Maastricht, Netherlands
Show 1 removed
  • Sheba Medical Center · Tel Litwinsky, Israel
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    7 sites added, 1 site removed. 7 sites changed recruiting status (4 now recruiting, 3 now withdrawn)
    Show 7 sites
    • University of Arizona · Tucson, United StatesRecruiting→Withdrawn
    • Centro Hospitalar Universitario do Porto · Porto, PortugalRecruiting→Withdrawn
    • Synexus Midlands Clinical Research Centre · Birmingham, United KingdomActive, not recruiting→Recruiting
    • Synexus Wales Clinical Research Centre · Cardiff, United KingdomActive, not recruiting→Recruiting
    • Synexus Scotland Clinical Research Centre · Glasgow, United KingdomActive, not recruiting→Recruiting
    • Synexus Hexham Clinical Research Centre · Hexham, United KingdomActive, not recruiting→Withdrawn
    • Synexus Manchester Clinical Research Centre · Manchester, United KingdomActive, not recruiting→Recruiting
    Show 7 added (2 Brazil, 1 United States, 1 Canada, 1 Germany, 1 Israel, 1 Netherlands)
    • University of Wisconsin - Madison · Madison, United States
    • UNICAMP · Campinas, Brazil
    • Instituto de Educacao, Pesquisa e Gestao em Saude · Rio de Janeiro, Brazil
    • Montreal Heart Institute · Montreal, Canada
    • LMU Klinikum Muenchen · Munich, Germany
    • Sheba Medical Center · Tel HaShomer, Israel
    • Maastricht University Medical Center · Maastricht, Netherlands
    Show 1 removed
    • Sheba Medical Center · Tel Litwinsky, Israel

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06128629
Lead sponsor
Intellia Therapeutics
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Dec 13, 2023
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial Manager at Intellia
Contact
medicalinformation@intelliatx.com
1-857-285-6200 ext. 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NTLA-2001

Start the discussion